Revolutionizing non-viral gene delivery with silicon-stabilized LNPs

“To me, the separation of nanoparticle formation from the loading of biological cargo—nucleic acid, protein, CAR-T cell, or stem cells—will be key for the field to progress.”

We spoke with Dr Suzanne Saffie-Siebert, Founder & CEO of SiSaf Ltd, exploring the potential of silicon stabilized hybrid lipid nanoparticle (sshLNP) technology for non-viral gene delivery. With applications spanning dermal, ophthalmic, and cancer treatments, she envisions sshLNPs as a transformative solution for personalized medicine, reduced cold-chain dependence, and efficient manufacturing, enabling the future of gene therapy.

Please enter your email to access content Read now